These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16354314)

  • 1. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
    Garst J; Buller R; Lane S; Crawford J
    Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
    J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
    Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
    Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.
    Lilenbaum RC; Huber RM; Treat J; Masters G; Kaubitzsch S; Lane S; Wissel P
    Clin Lung Cancer; 2006 Sep; 8(2):130-4. PubMed ID: 17026814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].
    Feng F; He X; Shi Y
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):155-8. PubMed ID: 11783024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.
    Huber RM; Reck M; Gosse H; von Pawel J; Mezger J; Saal JG; Kleinschmidt R; Steppert C; Steppling H
    Eur Respir J; 2006 Jun; 27(6):1183-9. PubMed ID: 16481389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of weekly topotecan in recurrent small cell lung cancer.
    Eckardt JR
    Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.